Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

F. Onida, LC. de Wreede, A. van Biezen, DJ. Eikema, JL. Byrne, AP. Iori, R. Schots, A. Jungova, J. Schetelig, J. Finke, H. Veelken, JE. Johansson, C. Craddock, M. Stelljes, M. Theobald, E. Holler, U. Schanz, N. Schaap, J. Bittenbring, E....

. 2017 ; 177 (5) : 759-765. [pub] 20170328

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17030913

Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030913
003      
CZ-PrNML
005      
20171025115410.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.14619 $2 doi
035    __
$a (PubMed)28369779
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Onida, Francesco $u Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
245    10
$a Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation / $c F. Onida, LC. de Wreede, A. van Biezen, DJ. Eikema, JL. Byrne, AP. Iori, R. Schots, A. Jungova, J. Schetelig, J. Finke, H. Veelken, JE. Johansson, C. Craddock, M. Stelljes, M. Theobald, E. Holler, U. Schanz, N. Schaap, J. Bittenbring, E. Olavarria, Y. Chalandon, N. Kröger,
520    9_
$a Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a přežívání štěpu $7 D006085
650    _2
$a transplantace hematopoetických kmenových buněk $x metody $x mortalita $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a leukemie myeloidní chronická atypická BCR-ABL-negativní $x mortalita $x terapie $7 D054438
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a recidiva $7 D012008
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
650    _2
$a homologní transplantace $7 D014184
655    _2
$a časopisecké články $7 D016428
700    1_
$a de Wreede, Liesbeth C $u Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands. DKMS Clinical Trials Unit, Dresden, Germany.
700    1_
$a van Biezen, Anja $u Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands.
700    1_
$a Eikema, Diderik-Jan $u Department of Medical Statistics & Bioinformatics, Leiden University Medical Centre, Leiden, The Netherlands.
700    1_
$a Byrne, Jenny L $u Nottingham University Hospitals Trust, Nottingham, UK.
700    1_
$a Iori, Anna P $u Azienda Policlinico Umberto I, 'La Sapienza' University, Rome, Italy.
700    1_
$a Schots, Rik $u Universitair Ziekenhuis Brussel, Brussels, Belgium.
700    1_
$a Jungova, Alexandra $u Charles University Hospital, Pilsen, Czech Republic.
700    1_
$a Schetelig, Johannes $u Universitaetsklinikum Dresden, Dresden, Germany.
700    1_
$a Finke, Jürgen $u University of Freiburg, Freiburg, Germany.
700    1_
$a Veelken, Hendrik $u Department of Haematology, Leiden University Medical Centre, Leiden, The Netherlands.
700    1_
$a Johansson, Jan-Erik $u Sahlgrenska University Hospital, Göteborg, Sweden.
700    1_
$a Craddock, Charles $u Queen Elisabeth Hospital, Birmingham, UK.
700    1_
$a Stelljes, Matthias $u University of Münster, Münster, Germany.
700    1_
$a Theobald, Matthias $u University Medical Centre Mainz, Mainz, Germany.
700    1_
$a Holler, Ernst $u University Regensburg, Regensburg, Germany.
700    1_
$a Schanz, Urs $u University Hospital, Zürich, Switzerland.
700    1_
$a Schaap, Nicolaas $u Radboud University - Nijmegen Medical Centre, Nijmegen, The Netherlands.
700    1_
$a Bittenbring, Jörg $u University Hospital, Homburg, Germany.
700    1_
$a Olavarria, Eduardo $u Hammersmith Hospital, London, UK.
700    1_
$a Chalandon, Yves $u Hematology Division, Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany.
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 177, č. 5 (2017), s. 759-765
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28369779 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025115453 $b ABA008
999    __
$a ok $b bmc $g 1254506 $s 991940
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 177 $c 5 $d 759-765 $e 20170328 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options